TAIWAN, April XNUMX / PRNewswire / -
- A computerized, rapid antigen analysis to avoid human error.
- A fully digitized screening solution delivers results in around 15 minutes.
- The SaaS solution enables companies to reopen with confidence.
iXensor Co., Ltd. (6734.TWO), the mobile health pioneer, today announced that its PixoTest® POCT COVID-19 antigen test has received the CE-IVD mark. iXensor offers a fully digitized end-to-end solution consisting of a rapid antigen test, a digital health and admin app and a web portal for organizations to prevent further outbreaks.
The PixoTest® solution from iXensor comprises a palm-sized analyzer that reads test results precisely, a digital health passport app, an admin app and a HIPAA-compliant web portal for health management. The fully digitized test and report design reduces the time from test to report to 15 minutes. Not only does the solution overcome the limitations of laboratory testing, it also allows it to scale up in large screening facilities, enabling business continuity and reopening.
Smartphone-based accurate results in 15 minutes:
With the PixoTest® POCT Analyzer, which reads out the test results objectively, health organizations and companies can minimize the risk of false-negative cases compared to rapid tests that are interpreted by human eyes.
Simultaneous reporting and issuing of a digital health passport:
The analysis device simultaneously transmits the test results to the users of the PixoHealth Pass app via an encrypted QR code. The digital health passport also records the app users' vaccination certificates and helps them move freely in the coming summer holiday season.
Mobile health technology addresses fake reviews:
The PixoHealth Pass Admin App is designed for organizations to verify the authenticity of PixoTest® test results with a simple scan. The Admin App protects the safety of organizations amid the pandemic by validating the forgery-proof, encrypted results displayed in the PixoHealth Pass App.
Superior accuracy meets EU standard:
In the prospective clinical study carried out in Brazil, the PixoTest® showed a sensitivity of 95% and a specificity of 98% for nasopharyngeal samples in the range from 0 to 7 days from the onset of symptoms (DSO). Another study in the US examined the clinical performance of anterior nasal specimens in symptomatic patients, which found a sensitivity of 92,8% and a specificity of 100%.
In order to meet the increasing demand for rapid COVID-19 tests for self-application, Dr. Peter Fitzgerald, chairman of iXensor and professor emeritus of medicine at Stanford University: “We use the core technology PixoTech® from iXensor to develop the smartphone-based self-test, with which we can detect COVID-19 anywhere and anytime test and track. I believe that a COVID-19 self-test at home will drastically shorten many transmission routes in order to stop the pandemic. "
iXensor, the pioneer of mobile health, transforms smartphones into mobile medical diagnostics in laboratory quality. In 2017 iXensor introduced the PixoTest® blood glucose monitoring system as the world's first camera-based blood test with FDA approval for smartphones. Based on the PixoTech® platform, iXensor specializes in self-tests at home and clinical point-of-care diagnostics in the areas of infectious diseases, women's health and cardiovascular diseases.